AICAR (Acadesine) is a cell-permeable purine nucleoside analog converted intracellularly to ZMP, mimicking AMP to allosterically activate AMPK in cellular bioenergetics, glucose uptake, and mitochondrial biogenesis assays.
Scientific Profile & Research Key Points: AICAR
AICAR (Acadesine) is a cell-permeable purine nucleoside analog converted intracellularly to ZMP, mimicking AMP to allosterically activate AMPK in cellular bioenergetics, glucose uptake, and mitochondrial biogenesis assays.
Active Batch Release Specifications (Lot SL-2026-105)
Analytical release verification for current AICAR (50 mg) inventory
| Batch Lot # | Release Date | Analytical Method | Purity Spec | Endotoxin (LAL) | Moisture |
|---|---|---|---|---|---|
| SL-2026-105 | 2026-10-28 | HPLC-UV + LC-MS (Small-Molecule Verification) | ≥99.0% (Chromatographic Peak) | <0.5 EU/mg | <2.8% (Karl Fischer) |
Laboratory Solubilization & Storage Protocol
Recommended Solvent / Handling
Sterile water (up to 15 mg/mL) or sterile DMSO (up to 50 mg/mL)
Temperature & Stability
Store solid powder at -20°C dry; store aqueous working stocks at -20°C in single-use aliquots.
AICAR — Technical Questions & Answers
What is the molar concentration when reconstituting AICAR (50 mg) in 2.0 mL?
Reconstituting the full 50 mg vial of AICAR (MW 258.23 g/mol) in 2.0 mL of diluent produces a 25.00 mg/mL stock solution — equivalent to approximately 96.81 mM (96,813 µM) gross molarity before Net Peptide Content (NPC) adjustment.
How does AICAR's salt form affect assay mass calculations?
AICAR (CAS 2627-69-2, formula C9H14N4O5) is supplied as Free base crystalline lyophilized solid. Because counterions and residual bound water contribute to gross lyophilized weight, quantitative receptor-binding assays should apply batch Net Peptide Content (NPC) or active-ion correction rather than gross cake weight alone.
Which analytical methods verify AICAR Lot SL-2026-105 and what pathway does it target?
Lot SL-2026-105 undergoes HPLC-UV + LC-MS (Small-Molecule Verification) confirming ≥99.0% (Chromatographic Peak) and identity against 258.23 g/mol. In preclinical literature, AICAR targets AMP-activated protein kinase (AMPK) (Narkar V.A. et al., Cell (2008) — AMPK and PPARδ agonists as exercise-mimetic research probes (PMID: 18674809)).
Related Scientific Monographs
Peer-reviewed mechanism summaries and analytical protocols
SLU-PP-332: Synthetic Pan-ERR Agonist Chemistry, DMSO Solubility & Mitochondrial Biogenesis
Analytical profile of small-molecule pan-ERR agonist SLU-PP-332 (CAS 303760-60-3): nuclear receptor EC50 selectivity, mitochondrial respiration models, and DMSO stock preparation.
Cagrilintide vs Retatrutide: Amylin/Calcitonin Receptors vs Triple Incretin Agonism
Biochemical comparison of long-acting amylin analogue Cagrilintide (AM833) against triple incretin agonist Retatrutide and dual-pathway Cagrilintide + Semaglutide combinations.
Survodutide vs Mazdutide vs Retatrutide: Dual GLP-1/Glucagon and Triple Agonist Biochemistry
Comparative receptor pharmacology of Survodutide (BI 456906), Mazdutide (IBI362), and Retatrutide (LY3437943): GLP-1R/GCGR/GIPR potency ratios and stability.
Related Metabolic & Incretin Research Compounds
View category →